Virax Biolabs Group Ltd (VRAX) — SEC Filings
Virax Biolabs Group Ltd (VRAX) — 27 SEC filings. Latest: 6-K (Apr 14, 2026). Includes 23 6-K, 2 20-F, 1 SC 13G/A.
View Virax Biolabs Group Ltd on SEC EDGAR
Overview
Virax Biolabs Group Ltd (VRAX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 14, 2026: Virax Biolabs Group Ltd filed a 6-K report on April 14, 2026, detailing its operations and business address at BIOCITY GLASGOW, BO'NESS ROAD, NEWHOUSE LANARKSHIRE, ML1 5UH. The filing includes various documents such as the 6-K report itself, an exhibit (EX-99.1), and graphic files, indicating ongoin
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 1 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Virax Biolabs Group Ltd is neutral.
Filing Type Overview
Virax Biolabs Group Ltd (VRAX) has filed 23 6-K, 2 20-F, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of VRAX's 21 recent filings, 1 were flagged as high-risk, 5 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Ian Martin
- James Foster
- Yair Erez
- Jason Davis
- Nigel James
Industry Context
Virax Biolabs operates in the in vitro and in vivo diagnostic substances industry. This sector is characterized by rapid technological advancements, stringent regulatory oversight, and intense competition from both established players and emerging companies. The recent shift away from COVID-19 specific diagnostics necessitates a strategic pivot towards broader diagnostic solutions and other life science applications.
Top Tags
sec-filing (7) · 6-k (7) · reporting (5) · 6-K (3) · foreign-issuer (2) · corporate-filing (2) · governance (2) · diagnostic-test (2) · regulatory-update (2) · foreign-private-issuer (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| 6-K Document Size | 27742 | Size of the primary 6-K filing document in bytes. |
| EX-99.1 Document Size | 34531 | Size of the exhibit document in bytes. |
| Revenue for FY2024 | £1,043,000 | 89.7% decrease from £10,147,000 in FY2023 |
| Net Loss for FY2024 | £10,037,000 | 77.9% increase from £5,640,000 in FY2023 |
| Equity interest acquired | 51% | in Shanghai Xitu Consulting Co., Limited |
| Acquisition cost | £1,000,000 | for 51% of Shanghai Xitu Consulting Co., Limited |
| Funds raised | £1,000,000 | from November 2022 private placement |
| Participants | 100 | Target enrollment for the clinical study |
| SEC File Number | 001-41440 | Identifies the company's filing with the SEC. |
| Gross Proceeds | $1.5M | Raised from registered direct offering on August 21, 2024. |
| Price Per Share | $1.00 | The purchase price for the ordinary shares in the direct offering. |
| Fiscal Year End | 0331 | Indicates the end of the reporting period for financial statements. |
| Filing Date | 20240820 | Date the 20-F report was submitted to the SEC. |
Frequently Asked Questions
What are the latest SEC filings for Virax Biolabs Group Ltd (VRAX)?
Virax Biolabs Group Ltd has 27 recent SEC filings from Jan 2024 to Apr 2026, including 23 6-K, 2 20-F, 1 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VRAX filings?
Across 27 filings, the sentiment breakdown is: 1 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Virax Biolabs Group Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Virax Biolabs Group Ltd (VRAX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Virax Biolabs Group Ltd?
Financial highlights for Virax Biolabs Group Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for VRAX?
The investment thesis for VRAX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Virax Biolabs Group Ltd?
Key executives identified across Virax Biolabs Group Ltd's filings include Ian Martin, James Foster, Yair Erez, Jason Davis, Nigel James.
What are the main risk factors for Virax Biolabs Group Ltd stock?
Of VRAX's 21 assessed filings, 1 were flagged high-risk, 5 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Virax Biolabs Group Ltd?
Forward guidance and predictions for Virax Biolabs Group Ltd are extracted from SEC filings as they are enriched.